Searchable abstracts of presentations at key conferences in endocrinology

ea0041oc5.3 | Neuroendocrinology | ECE2016

Development of a long-acting growth hormone antagonist for the treatment of acromegaly

Wilkinson Ian , Pradhananga Sarbendra , Speak Rowena , Sayers Jon , Ross Richard

Background: The UK acromegaly register reported that <60% of acromegalics on medical therapy had controlled disease (1). Pegvisomant, a growth hormone antagonist (GHA), controls disease in >95% cases, but is not cost-effective and requires high dose daily injections (2). We have developed a fusion technology for making a cost-effective long-acting GH molecule (3), and generated a GHA by linking mutated growth hormone to its binding protein (GHBP).<p class="abstext"...

ea0034oc5.6 | Pituitary | SFEBES2014

A GH antagonist fusion with GH binding protein is biologically active, shows delayed clearance and inhibits growth in a rabbit model

Wilkinson Ian , Phipps Michael , Sayers Jon , Artymiuk Peter , Ross Richard

Background: Acromegaly is associated with increased morbidity and mortality, however currect medical treatment controls the disease in <60% of patients. Pegvisomant, a pegylated GH antagonist, controls the disease in over 95% of cases, but is not cost effective as it requires high dose daily injections and has side-effects. We have developed a technology for generating a long acting potent GH antagonist.Hypothesis: That a GH antagonist fused to GH bi...

ea0031p42 | Clinical biochemistry | SFEBES2013

Glycosylated linkers to generate long-acting GH tandems

Wilkinson Ian , Cawley Pippa , Bielohuby Maximilian , Sayers Jon , Artymiuk Peter , Bidlingmaier Martin , Ross Richard

Background: The development of recombinant biologics has had a major impact on many diseases. However, most biologics are rapidly cleared from the body and therefore require frequent injection regimens. There is therefore a need for technologies that allow the half-lives of these molecules to be extended in a predictable manner.HypothesisIncreasing numbers of N-linked glycosylation motifs between two GH molecules leads to gradually...

ea0028p242 | Pituitary | SFEBES2012

Development of a platform technology to generate long-acting protein therapeutics

Parry Heather , Thorpe Alice , Wilkinson Ian , Pradnanhanga Sarbendra , Sayers Jon , Artymiuk Peter , Ross Richard

Background: The development of recombinant biologics such as interferon, insulin and Growth Hormone (GH) has had a major impact on the management of diseases including hepatitis, diabetes and GH-deficiency. However, most biologics undergo rapid renal filtration and proteolytic degradation, necessitating frequent dosing regimens. Pegylation can successfully delay clearance but has several drawbacks including potential toxicity, expense and reduced activity. There is therefore n...